Related Experiment Video
Updated: May 3, 2026

Detecting Glycogen in Peripheral Blood Mononuclear Cells with Periodic Acid Schiff Staining
Published on: December 23, 2014
Glycogenosome accumulation in the arrector pili muscle in Pompe disease
Istvan Katona1, Joachim Weis, Frank Hanisch
1Institute of Neuropathology, RWTH Aachen University and JARA Brain Translational Medicine, Pauwelsstr, 30, 52074 Aachen, Germany. ikatona@ukaachen.de.
Background:
Glycogenosis type II or Pompe disease is an autosomal-recessive lysosomal storage disease due to mutations in the gene encoding acid alpha-glucosidase (GAA), an enzyme required for lysosomal glycogen degradation. The disease predominantly affects the skeletal and respiratory muscles but there is growing evidence of the involvement of smooth muscle cells in blood vessel walls, suggesting a multi-system disorder. Moreover, the failure of autophagy in Pompe disease could contribute to muscular atrophy and disease progression and is thought to compromise the efficacy of enzyme replacement therapy (ERT).
Methods:
We investigated the light microscopical and ultrastructural pathology of the arrector pili muscle from punch skin biopsies from the calf of 6 adult Pompe disease patients and 6 age and gender matched healthy controls. Two patients had a follow-up biopsy after 19 and 20 month of ERT.
Results:
The electron microscopic investigation of patient biopsies revealed the widespread occurrence of glycogenosomes, membrane bound accumulations of granular glycogen, associated with autophagic vacuoles. In the controls we detected only muscle cells with non-membrane bound forms of glycogen. These morphological changes in smooth muscle cells are similar to those seen in skeletal muscle and smooth muscle cells of arterioles of Pompe patients. Furthermore, two patients with pre- and post-ERT skin biopsies showed a decrease in the number of cells with extensive autophagy after treatment.
Conclusions:
Electron microscopic examination of the arrector pili muscles appears to be a surrogate marker for the involvement of smooth muscles reflecting disease severity. These findings suggest that the standardized and widely used skin biopsy could offer a minimally invasive way to screen for smooth muscle involvement and warrant further studies in larger cohorts of patients.
Insights
Skin biopsies reveal that arrector pili muscles in Pompe disease patients accumulate glycogen, indicating smooth muscle involvement. Enzyme replacement therapy may reduce autophagy in these smooth muscles.
Area of Science:
- Biochemistry
- Genetics
- Pathology
Background:
- Pompe disease (Glycogenosis type II) is a genetic disorder caused by acid alpha-glucosidase (GAA) deficiency, leading to glycogen buildup.
- While primarily affecting skeletal and respiratory muscles, Pompe disease increasingly shows smooth muscle cell involvement, suggesting a multi-systemic nature.
- Autophagy dysfunction in Pompe disease may drive muscle atrophy and reduce enzyme replacement therapy (ERT) efficacy.
Purpose of the Study:
- To investigate the ultrastructural pathology of arrector pili muscles in Pompe disease patients.
- To assess the impact of enzyme replacement therapy (ERT) on smooth muscle pathology in Pompe disease.
Main Methods:
- Electron microscopy of arrector pili muscle from skin biopsies of 6 Pompe disease patients and 6 controls.
- Comparison of pre- and post-ERT biopsies from two patients.
Main Results:
- Pompe disease patients exhibited glycogenosomes and autophagic vacuoles in arrector pili smooth muscle cells, unlike controls.
- Morphological changes in these smooth muscles mirrored those in skeletal muscles and arterioles of Pompe patients.
- ERT led to a reduction in cells with significant autophagy in treated patients.
Conclusions:
- Arrector pili muscle examination via electron microscopy serves as a potential surrogate marker for smooth muscle involvement and disease severity in Pompe disease.
- Skin biopsies offer a minimally invasive method to screen for smooth muscle pathology in Pompe disease.
- Further research with larger patient cohorts is warranted to validate these findings.
More Related Videos
Related Concept Videos
Alterations in Muscle Tone lll
Myasthenia Gravis ll: Pathophysiology
Cardiomyopathy III: Hypertrophic Cardiomyopathy

